Published online before print May 27, 2003, doi: 10.1161/01.HYP.0000075082.06183.4E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;42:31.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Imbalance of T-Cell Subsets in Angiotensin II–Infused Hypertensive Rats With Kidney Injury
From the Division of Nephrology and Endocrinology, University of Tokyo School of Medicine (J.S., M.N., K.Y., T.F.), Tokyo, and the Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine (T.M., R.I., K.K.), Isehara, Kanagawa, Japan.
Correspondence to Dr Masaomi Nangaku, Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail mnangaku-tky{at}umin.ac.jp
Blockade of angiotensin (Ang) II is efficient in various renal diseases. Although interest has focused on the hemodynamic changes and reduction of proteinuria, recent studies emphasize the nonhemodynamic effects of Ang II on kidney injury. The aim of this study was to clarify the mechanisms of Ang II on the immune system that alter the balance of helper T-cell (Th) subsets. We used a continuous, Ang II infusion model of rats that develop hypertension, proteinuria, and tubulointerstitial damage, including de novo expression of 
-smooth muscle actin and loss of endothelial cells. We isolated T cells from the spleen and measured cytokine levels by ELISA systems. Ang II–infused rats showed an increase in the Th1 cytokine 
-interferon and a decrease in the Th2 cytokine interleukin-4. The same change in cytokine mRNA expression in the spleen and kidney was confirmed by quantitative polymerase chain reaction analysis. Our ELISPOT assay showed an increase in the number of -interferon–secreting T cells by Ang II. To investigate whether these changes were specific effects of Ang II, we treated the model rats with the Ang II receptor blocker (ARB) olmesartan or the nonspecific vessel dilator hydralazine. Administration of the ARB ameliorated disease manifestations and the imbalance in Th subsets, whereas hydralazine did not, despite comparable effects on blood pressure. These results demonstrate a direct role of Ang II in the modification of Th balance. The imbalance of Th subsets was associated with hypertensive kidney injury induced by Ang II. Some of the beneficial effects of ARBs might be explained by their immunomodulatory reactions.
Key Words: angiotensin • angiotensin II type 1 receptor blocker • helper T cell • tubulointerstitial damage • cytokines
This article has been cited by other articles:
 |
|
 |
|
  S. Verlohren, D. N. Muller, F. C. Luft, and R. Dechend Immunology in Hypertension, Preeclampsia, and Target-Organ Damage Hypertension, September 1, 2009; 54(3): 439 - 443. [Full Text] [PDF]
|
|
|
|
|
|
P. Mathieu, P. Poirier, P. Pibarot, I. Lemieux, and J.-P. Despres Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease Hypertension, April 1, 2009; 53(4): 577 - 584. [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Crowley, C. W. Frey, S. K. Gould, R. Griffiths, P. Ruiz, J. L. Burchette, D. N. Howell, N. Makhanova, M. Yan, H.-S. Kim, et al. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension Am J Physiol Renal Physiol, August 1, 2008; 295(2): F515 - F524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Kawajiri, M Mogi, M Osoegawa, T Matsuoka, K Tsukuda, K Kohara, M Horiuchi, T Miki, and J. Kira Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 557 - 560. [Abstract] [PDF]
|
|
|
|
|
|
J.-K. Park, R. Fischer, R. Dechend, E. Shagdarsuren, A. Gapeljuk, M. Wellner, S. Meiners, P. Gratze, N. Al-Saadi, S. Feldt, et al. p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II-Induced Target Organ Damage Hypertension, March 1, 2007; 49(3): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Long, W. Mu, K. L. Price, C. Roncal, G. F. Schreiner, A. S. Woolf, and R. J. Johnson Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1248 - F1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hallenbeck, G. del Zoppo, T. Jacobs, A. Hakim, S. Goldman, U. Utz, A. Hasan, and for the Immunomodulation Workshop Participants Immunomodulation Strategies for Preventing Vascular Disease of the Brain and Heart: Workshop Summary Stroke, December 1, 2006; 37(12): 3035 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yu, K. Horak, and D. F. Larson Role of T Lymphocytes in Hypertension-Induced Cardiac Extracellular Matrix Remodeling Hypertension, July 1, 2006; 48(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miyata and C. van Ypersele de Strihou Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering Nephrol. Dial. Transplant., April 1, 2006; 21(4): 846 - 849. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Inagi, Y. Yamamoto, M. Nangaku, N. Usuda, H. Okamato, K. Kurokawa, C. van Ypersele de Strihou, H. Yamamoto, and T. Miyata A Severe Diabetic Nephropathy Model With Early Development of Nodule-Like Lesions Induced by Megsin Overexpression in RAGE/iNOS Transgenic Mice Diabetes, February 1, 2006; 55(2): 356 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nangaku Chronic Hypoxia and Tubulointerstitial Injury: A Final Common Pathway to End-Stage Renal Failure J. Am. Soc. Nephrol., January 1, 2006; 17(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Izuhara, M. Nangaku, R. Inagi, N. Tominaga, T. Aizawa, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3631 - 3641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Yu, R. R. Watson, J. J. Marchalonis, and D. F. Larson A role for T lymphocytes in mediating cardiac diastolic function Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H643 - H651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Inokuchi, T Morohashi, I Kawana, Y Nagashima, M Kihara, and S Umemura Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice Gut, March 1, 2005; 54(3): 349 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassmann, T. Czech, M. van Eickels, I. Fleming, M. Bohm, and G. Nickenig Inhibition of Diet-Induced Atherosclerosis and Endothelial Dysfunction in Apolipoprotein E/Angiotensin II Type 1A Receptor Double-Knockout Mice Circulation, November 9, 2004; 110(19): 3062 - 3067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui and Z. Mallat Hypertension: A Novel Regulator of Adaptive Immunity in Atherosclerosis? Hypertension, September 1, 2004; 44(3): 257 - 258. [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Neri Serneri, M. Boddi, P. A. Modesti, M. Coppo, I. Cecioni, T. Toscano, M. L. Papa, M. Bandinelli, G. F. Lisi, and M. Chiavarelli Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component Circ. Res., June 25, 2004; 94(12): 1630 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Manotham, T. Tanaka, M. Matsumoto, T. Ohse, T. Miyata, R. Inagi, K. Kurokawa, T. Fujita, and M. Nangaku Evidence of Tubular Hypoxia in the Early Phase in the Remnant Kidney Model J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1277 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chon, C. A.J.M. Gaillard, B. B. van der Meijden, H. M. Dijstelbloem, R. J. Kraaijenhagen, D. van Leenen, F. C.P. Holstege, J. A. Joles, H. A.R. Bluyssen, H. A. Koomans, et al. Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension Is Absent During Treatment Hypertension, May 1, 2004; 43(5): 947 - 951. [Abstract] [Full Text] [PDF]
|
|